Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 784

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 4
Chunk 784
---
 another source, or (iii) the expiration of Mr.
Arnold’s eligibility for the continuation coverage. Further, and pursuant to the Arnold Separation Agreement, Mr. Arnold provided
the Company with a general release of all claims, effective July 1, 2024.

 77 

Employment Arrangements

We currently have written
employment agreements with our executive officers. For information about our employment agreements with our named executive officers,
refer to “Executive and Director Compensation — Employment Contracts.”

Equity Awards Granted to Executive Officers
and Directors

We have granted stock options
and RSUs to our executive officers and directors. For information about our grants of stock option awards and RSUs to our named executive
officers and our directors, refer to “Executive and Director Compensation — Outstanding Equity Awards at
2024 Fiscal Year-End,” “Executive and Director Compensation — Director Compensation for 2024 Fiscal
Year” and “Executive and Director Compensation — Non-Employee Director Compensation Policy.”

Indemnification Agreements

We have entered into and intend
to continue to enter into indemnification agreements with each of our directors and our officers. The indemnification agreements, our
Articles of Incorporation, as amended, and our Amended and Restated Bylaws require us to indemnify our directors and officers to the fullest
extent permitted by Nevada law.

Policies and Procedures for Transactions with
Related Persons

We maintain a written policy
that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common
stock and any members of the immediate family or affiliate of any of the foregoing persons are not permitted to enter into a related person
transaction with us without the approval or ratification of the Audit Committee. Any request for us to enter into a transaction with an
executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock, or
any member of the immediate family or affiliate of any of the foregoing persons, in which the amount involved exceeds $120,000 and such
person would have a direct or indirect interest, must be presented to the Audit Committee for review, consideration and approval. In approving
or rejecting any such proposal, the Audit Committee is to consider the material facts of the transaction, including whether the transaction
is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and
the extent of the related